Generali Asset Management SPA SGR bought a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 434,919 shares of the biopharmaceutical company's stock, valued at approximately $11,538,000.
A number of other hedge funds have also recently made changes to their positions in the company. Retirement Wealth Solutions LLC acquired a new stake in Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the fourth quarter worth $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer in the fourth quarter worth $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer in the fourth quarter valued at $31,000. Finally, Curio Wealth LLC bought a new position in Pfizer during the 4th quarter worth $32,000. 68.36% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on the company. StockNews.com downgraded Pfizer from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 20th. Bank of America restated a "neutral" rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Citigroup reduced their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday. Finally, UBS Group cut their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $31.92.
View Our Latest Research Report on PFE
Insider Buying and Selling
In other news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is owned by corporate insiders.
Pfizer Stock Down 0.5 %
Shares of NYSE PFE traded down $0.14 during midday trading on Wednesday, hitting $26.18. 27,238,712 shares of the stock traded hands, compared to its average volume of 35,768,108. The business has a 50 day moving average price of $26.21 and a two-hundred day moving average price of $27.09. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a market cap of $148.34 billion, a PE ratio of 18.59, a P/E/G ratio of 0.64 and a beta of 0.61.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company's quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.10 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
